US FDA Weighs Patent Listing Requirements For Digital Apps Used With Drugs

Agency is considering whether patents for digital apps used in conjunction with approved drugs should be listed in the 'Orange Book’; modernization plan for the compendium includes new guidance on therapeutic equivalence ratings to help clarify path for fully substitutable 505(b)(2) NDA products.

Black Office Folder with Inscription Patents on Office Desktop with Office Supplies and Modern Laptop. Patents Business Concept on Blurred Background. Patents - Toned Image. 3D. - Illustration

The US FDA is weighing whether patents covering digital applications used with approved drugs should be listed in the “Orange Book” as part of the agency’s efforts to modernize the compendium.

In a Jan. 30 announcement about new guidance and other initiatives aimed at making the Orange Book a more useful...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement

 
• By 

Lupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Generic Drug Office’s Policy Staff Returning To US FDA

 

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

More from Biosimilars & Generics